In this study, researchers are testing a treatment called **tralokinumab**, given by shots under the skin (called *subcutaneous injections*), along with a cream called **topical corticosteroids (TCS)**, to help kids with a skin problem called **atopic dermatitis (AD)**. AD is a condition that makes skin red, itchy, and swollen. The study will check if these treatments are safe and help make the skin better. The study lasts up to 4 years, with visits every 2 weeks for the first year, then every 6 weeks. Some visits will be by phone.

The study is for kids aged 6 months to under 12 years. Children will get either tralokinumab + TCS or a pretend treatment (placebo) + TCS for the first 16 weeks, but everyone will know infants only get the real treatment. After 16 weeks, all kids will get tralokinumab + TCS. After the treatment stops, there’s a 4-week safety check.

• Visits are frequent: every 2 weeks initially, then every 6 weeks.
• Some children may receive a placebo for the first 16 weeks.
• The trial lasts up to 4 years, with a mix of in-person and phone visits.